Tech Track 100

This firm’s Siltuximab drug was given regulatory approval in America in July for a phase three clinical trial treating patients with Covid-19, after seeing success in improving patient survival rates. The company has already had direct orders for the drug from the governments of Belgium and Belarus. It was founded by chief executive Lee Morley, 50, and chief financial officer Emma Johnson, 39, who spun the firm out of Jazz Pharmaceuticals in 2015. Sales grew to £92.6m in 2019, thanks to the success of a number of drugs the firm has acquired, including those that treat cancers in children, which Eusa Pharma has been able to make available in more countries.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2020
Rank59
CompanyEUSA Pharma
ActivityBiopharmaceuticals developer
LocationHemel Hempstead
Average 3 year sales growth70.45%
Latest sales £000s92,628
Staff115
Founded2015
Websitewww.eusapharma.com

If applicable:

* supplied by company † annualised figure